Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1999-10-07
2002-06-25
Priebe, Scott D. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S003100, C514S012200, C530S303000, C530S308000, C424S184100, C424S198100, C435S069100, C435S325000, C435S243000
Reexamination Certificate
active
06410508
ABSTRACT:
BACKGROUND OF THE INVENTION
The United States government has rights in this invention by virtue of NIH grants DK-19813 and HD 34149 and Yale Core Center for Musculoskeletal Disorders P30 AR46032.
Glucose-dependent Insulinotropic Peptide (GIP) is a 42 amino acid peptide synthesized and secreted from endocrine cells in the small intestine. GIP's role in coupling nutrient intake and insulin secretion, the “incretin” effect, is well known. Parathyroid hormone and vitamin D are known to couple calcium intake to bone formation but no coupling hormone has been identified for nutrient intake and bone formation.
GIP is secreted from enteric endocrine cells in the proximal small intestine, whereas glucagon-like peptide 1 (GLP-1, another major “incretin” hormone) is secreted from endocrine cells in the terminal small bowel. Until recently, the glucose-dependent insulinotropic peptide (GIP) had been considered a parochial hormone of the enteric endocrine system with its major site of action being the &bgr;-cells of the endocrine pancreas. R. A. Pederson, et al.,
Endocrinology
99, 780-785 (1976). However, the cloning of the GIP receptor led to the discovery that the receptor is expressed in a wide range of tissues and organs, including the exocrine pancreas, and distal small cells in several vascular beds. T. B. Usdin, et al.,
Endocrinology
133,2861-2870 (1993).
This widespread receptor distribution suggests as yet undefined physiological actions of GIP. Most studies seeking to define the actions of GIP have focused on synergism between GIP and glucose in stimulating insulin secretion. GIP infusions have also been shown to inhibit effects of glucagon on the liver while enhancing those of insulin, and to have dual effects on hepatic blood flow, increasing flow through the portal vein and inhibiting flow through the hepatic artery. Ironically, the effect for which GIP was discovered, inhibition of gastric acid secretion, seems to be a minor pharmacological effect of little physiological significance.
At present the main modulator of bone metabolism is thought to be the PTH-Vitamin D axis. Parathyroid hormone is known to be negatively regulated by nutrient absorption, with PTH secretion decreasing after a calcium-rich meal and rising during fasting W. Jubiz, et al.,
J Clin Invest
51, 2040-2046 (1972). Receptors for PTH are found on osteoblasts and PTH-induces cytokine expression which in tun modulates osteoclastic activity, J. E. Onyia, et al.,
J Cell Biochem
67, 265-74 (1997), J. H. Pollock, et al.,
J Bone Miner Res
11, 754-9 (1996). Thus, PTH-induced bone turnover is generally a coupled process and, in conjunction with Vitamin D, PTH plays a major role in bone mineralization.
In addition to calcium intake, however, bone depends for its growth and remodeling on nutrient intake. In fact, even in a state of high bone turnover, such as in an ovariectomized rat, it is possible to prevent bone loss by altering the rat's diet and placing her on a specified protein diet, B. H. Arjmandi, et al.,
J Nutr
126, 161-167 (1996), suggesting that a gut-induced signal may modulate bone turnover. To date, the hormones of the enteric endocrine system have not been considered to play a major role in coordinating nutrient intake with skeletal growth and remodeling.
It is therefore an object of the present invention to provide a means for regulating skeletal growth and remodeling.
It is a further object of the present invention to provide therapeutic formulations for treatment of disorders such as osteoporosis.
SUMMARY OF THE INVENTION
The examples demonstrate that GIP receptor mRNA and protein are present in normal bone and osteoblastic-like cell lines, and that high-affinity receptors for GIP can be demonstrated by
125
I GIP binding studies. When applied to osteoblast-like cells (SaOS2), GIP stimulated an increase in cellular cAMP content and in intracellular calcium, with both responses being dose dependent. Moreover, administration of GIP results in elevated expression of collagen type I mRNA as well as an increase in alkaline phosphatase activity. Both of these effects reflect anabolic actions of presumptive osteoblasts. These results provide the first evidence that GIP receptors are present in bone and osteoblastic like cells and that GIP modulates the function of these cells.
GIP has anabolic actions on remodeling bone, increasing vertebral bone density in a rat model of osteoporosis. GIP at 10 nM inhibits PTH-induced bone resorption in a fetal long bone assay and stimulates the synthesis of type 1 collagen mRNA. Transgenic mice overexpressing GIP have increased bone density compared to same age controls.
GIP or analoges thereof can therefore be used as a therapeutic to inhibit bone resorption and to maintain or increase bone density. GIP antagonists, compounds which block binding to the GIP receptor, can be used to decrease bone density.
REFERENCES:
patent: 3625214 (1971-12-01), Higuchi
patent: 4244946 (1981-01-01), Rivier et al.
patent: 4305872 (1981-12-01), Johnston et al.
patent: 4316891 (1982-02-01), Guillemin et al.
patent: 4629784 (1986-12-01), Stammer
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 4868116 (1989-09-01), Morgan et al.
patent: 4906474 (1990-03-01), Langer et al.
patent: 4925673 (1990-05-01), Steiner et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 0 269 072 (1988-06-01), None
patent: 0 479 210 (1992-04-01), None
patent: WO 93/01286 (1993-01-01), None
patent: WO 98/24464 (1998-06-01), None
Kundu et al, Peptides 20:523-537, 1999.*
Ziegler et al, Steroids 63:344-348, 1998.*
Bollag et al, Endocrinology, 141(3):1228-35, 2000.*
Rosenberg et al., Gene Therapists, Heal Thyself, Mar. 2000, Science, vol. 287 p. 1751.*
Verma, Gene Therapy: Beyond 2000, Jun. 2000, Molecular Therapy, vol. 1 No. 6 p. 493.*
Verma et al., Gene therapy-promises, problems and prospects, Sep. 1997, Nature, vol. 389 pp. 239-242.*
Anderson, Human gene therapy, Apr. 1998, Nature, vol. 392 pp. 25-30.*
Touchett, Gene therapy: Not ready for prime time, Jan. 1996, Nature Medicine, vol. 2 No. 1 pp. 7-8.*
Bollag, et al., “Glucose-dependent insulinotropic peptide has anabolic effects of osteoblastic-like cells,”J. Bone Min. Res.14:S345 (1999).
Tseng, et al., “Glucose-dependent insulinotropic peptide structure of the precursor and tissue-specific expression in rat,”Proc. Natl. Acad. Sci. USA90:1992-1996 (1993).
Abou-Samra, et al., “Expression cloning of a common receptor for parathyroid.hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium,”Proc Natl Acad Sci U S A89(7):2732-6 (1992).
Agrawal, et al., “Oligodeoxynucleoside phosphoroamidates and phosphorothioates as inhibitors of human immunodeficiency virus,”Proc. Natl. Acad. Sci. USA85(19):7079-7083 (1988).
Amizuka, et al., “Programmed cell death of chondrocytes and aberrant chondrogenesis in mice homozygous for parathyroid hormone-related peptide gene deletion,”Endocrinology.137(11):5055-67 (1996).
Arjmandi, et al., “Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis,”J Nutr.126(1):161-7 (1996).
Askew, et al., “Molecular Recognition with Convergent Functional Groups, 6, Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components,”J. Am. Chem. Soc.,111:1082-1090 (1989).
Blume, et al., “Triple Helix Formation by Purine-rich Oligonucleotides Targeted to the Human Dihydrofolate Reductase Promoter.”Nucl. Acids Res. 20:1777-1784 (1992).
Campos, et al., “Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse,”Endocrinology.134(5):2156-64 (1994).
Clackson, et al., “Making antibody fragments using phage display libraries,”Nature.352(6336):624-8 (1991).
Cooney, et al., “Site-Specific Oligonucleotide Binding Represses Transcription of the Human c-myc Gene in Vitro,”Science241:456-459 (1988).
Crooke, “Progress Toward Oligonucleotide Therapeutics: Pharmacodynam
Bollag Roni J.
Isales Carlos M.
Rasmussen Howard
Kaushal Sumesh
Priebe Scott D.
Rothschild, Esq Cynthia B.
LandOfFree
Glucose-dependent insulinotropic peptide for use as an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glucose-dependent insulinotropic peptide for use as an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucose-dependent insulinotropic peptide for use as an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2939990